Insulin Clinics / Special situations

Cost and access

Insulin should not be a financial decision, but in the United States it often is. This page covers what your real options are, including the ones most people are not told about.

Medically reviewed by [Name, MD] · Last reviewed: [Month YYYY]

Why insulin is expensive in the U.S.

Insulin was invented in 1921 and the original patent was sold for one dollar so that, in the inventors' words, "insulin belongs to the world." A century later, insulin in the United States can list at $300 or more per vial, while the same product sells for a fraction of that price in Canada, the U.K., or Mexico.

Several factors drive U.S. prices:

• Three manufacturers — Eli Lilly, Novo Nordisk, and Sanofi — make most of the insulin sold here.
• List prices and net prices diverge. The list price is what shows on a pharmacy bill; the net price (after rebates to pharmacy benefit managers and insurers) is much lower. Patients with deductibles or no insurance pay something close to the list price; insurers and large purchasers do not.
• Patent strategies have kept biosimilar competition limited compared with other drug classes, though this is changing.
• The PBM (pharmacy benefit manager) system ties drug coverage to rebates, which historically rewarded high list prices.

This is not your fault, and it is not your prescriber's fault. It is the system you are navigating. The following sections are about the levers that actually exist.

The $35 copay cap (Medicare)

Since 2023, the federal Inflation Reduction Act caps out-of-pocket cost for covered insulin at $35 per month per insulin product for people on Medicare Part D and Part B. The cap applies regardless of whether the deductible has been met. If you are on Medicare and paying more than $35 per insulin per month, call your plan — there is almost certainly an error in how it is being processed.

Several states have passed their own caps for state-regulated commercial insurance, ranging from $25 to $100 per month. These are state-by-state and do not apply to self-funded employer plans (which are federally regulated). Your state insurance commissioner's website will list current rules.

Manufacturer copay caps and patient assistance

All three insulin manufacturers have now extended a $35-or-less monthly cap to most U.S. patients regardless of insurance status, through their own programs. Programs and eligibility change; always confirm at the manufacturer's site or hotline before counting on a number.

The patient assistance programs (PAPs) — separate from the cash savings cards — provide free insulin for people whose income falls below specific thresholds (typically around 400 percent of the federal poverty level) and who do not have prescription coverage. They take a few weeks to set up but ship insulin to your prescriber for pickup.

Biosimilars and authorized generics

Several lower-priced insulins are now available as biosimilars or authorized generics:

• Insulin glargine: Basaglar (Lilly), Semglee (Mylan/Biocon — interchangeable biosimilar), Rezvoglar (interchangeable biosimilar), Lantus authorized generic.
• Insulin lispro: Lilly's authorized generic of Humalog at a much lower list price; Admelog (Sanofi).
• Insulin aspart: Novo Nordisk's authorized generic of Novolog.

"Interchangeable" biosimilars (Semglee, Rezvoglar) can be substituted for the brand-name product by a pharmacist without contacting the prescriber. Other biosimilars require a new prescription. If you are paying full price for brand-name insulin, ask the pharmacist whether a biosimilar or authorized generic version exists for what you take and what it would cost.

The Walmart ReliOn line

Walmart sells older insulins under the ReliOn brand for substantially less than analog insulins, often around $25 per vial:

• ReliOn Novolin R — regular human insulin (short-acting).
• ReliOn Novolin N — NPH (intermediate-acting).
• ReliOn 70/30 — premixed NPH/regular.
• ReliOn NovoLog — insulin aspart (rapid-acting analog), introduced in 2021 at a substantially lower price than other analogs.

Important caveats:

• Regular and NPH are not interchangeable with analog insulins. Regular insulin needs to be taken about 30 minutes before meals, not at the start of a meal. NPH peaks 4–8 hours after injection, which is different from glargine, detemir, or degludec. Switching from analog to human insulin without a clinician's plan can cause serious problems.
• Some are sold without a prescription in many U.S. states (regular, NPH, and 70/30); the analog ReliOn NovoLog requires a prescription.
• For people with type 1 diabetes, switching from analog to regular and NPH is sometimes done in genuine financial emergencies but should always involve the care team — the timing differences make hypoglycemia and DKA risk meaningfully higher.
• For type 2 diabetes on basal alone, NPH at bedtime is a reasonable lower-cost option for many people, but should still be a medical decision rather than a self-substitution.

If you have been quietly switching to ReliOn because you can't afford your analog prescription, tell your clinician — they can help make the switch safer, or look at alternatives.

340B and community health centers

Federally Qualified Health Centers (FQHCs) and other 340B-covered entities receive sharply discounted prices on outpatient drugs, including insulin. Many pass at least some of those savings on to patients on a sliding-scale basis. Community health centers exist in nearly every U.S. county; the federal HRSA "Find a Health Center" tool lists them. Many serve patients regardless of insurance status.

Other options

• State pharmaceutical assistance programs. Many states have programs for older adults, people with disabilities, or people with low income.
• GoodRx and similar discount cards. They do not work with insurance, but they sometimes beat insurance cash prices for cash-paying patients.
• 340B mail-order pharmacies through some health systems.
• Hospital charity care. Most nonprofit hospitals are required to have financial assistance programs that cover medications; these are often poorly advertised but real.
• Civica Rx (under the Civica brand) is a nonprofit manufacturer planning to make low-cost generic glargine, aspart, and lispro available with a target price of around $30 per vial; check civicarx.org for current availability in your state.
• Mark Cuban Cost Plus Drug Company offers some diabetes medications at transparent low prices — check costplusdrugs.com for current insulin availability.

If you cannot afford insulin this week — do this

In order, until something works:

1. Call your prescriber's office. Tell them you cannot afford this prescription. Most clinics keep manufacturer sample pens in the office and can give you a few days' supply while a longer-term plan is built. They can also switch the prescription to a lower-cost biosimilar or to ReliOn safely.
2. Call the manufacturer hotline for your insulin (numbers above). Ask about the savings card and the patient assistance program.
3. Ask the pharmacist what the cash price is for the same insulin under any savings card or coupon, and whether a biosimilar is available.
4. Walk into a Walmart for ReliOn if a same-day option is needed and your prescriber agrees. Regular and NPH are sold without a prescription in most states.
5. Find a Federally Qualified Health Center using HRSA's Find a Health Center tool. Many can see new patients on short notice and can prescribe at 340B prices.
6. Call a diabetes nonprofit. Several organizations (the JDRF/Breakthrough T1D, Beyond Type 1, and the Diabetes Patient Advocacy Coalition among others) maintain emergency-bridge programs and can connect people to local resources.
7. Go to an emergency department if you are running out and cannot reach any of the above. ERs cannot turn you away under EMTALA; you may not get a perfect long-term solution there, but you will not be left without insulin.

What you should not do is silently stretch your insulin — using less than prescribed to make supplies last. Studies estimate roughly one in four U.S. patients with diabetes has done this at some point. It is the leading preventable cause of DKA, which costs more, hurts more, and can kill. The phone calls above are uncomfortable; the alternative is much worse.